ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)
ARS Pharmaceuticals (SPRY) reported Finished Goods of $7.3 million for Q1 2025, up 39.49% sequentially from $5.2 million in Q4 2024.
ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 2 years of Finished Goods data on file, last reported at $7.3 million in Q1 2025.
- For the quarter ending Q1 2025, Finished Goods changed N/A year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2025 stood at $7.3 million (changed N/A YoY), and the FY2024 full-year result was $5.2 million, changed N/A from the prior year.
- Finished Goods climbed to $7.3 million in Q1 2025, from $5.2 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $7.3 million in Q1 2025 to a low of $5.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 7.27 Mn |
| Dec 31, 2024 | 5.21 Mn |